Addition Of Celebrex PRECISION Cardiovascular Trial to Label Emphasizes Use Of Lowest Dose
Executive Summary
Heeding concerns of an advisory panel, US agency underscores that it is the lowest approved dose of the COX-2 inhibitor that has comparable CV risk to moderate doses of ibuprofen and naproxen.
You may also be interested in...
Celebrex PRECISION Trial: 'Herculean' Effort, But Missing Information Bugs US FDA Panel
Pfizer study finds Celebrex's CV risk comparable to naproxen and ibuprofen, but advisory committee wanted data on confounding factors and reasons for high dropout.
Celebrex Likely To Get Label Change Saying CV Risk Is Comparable To Ibuprofen, Naproxen
Despite concerns about difference in dosages and study discontinuation rates, US FDA advisory committee concludes that Pfizer's study demonstrated similar CV risk among the three NSAIDs.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.